TY  - JOUR
AU  - Grujić-Milanović, Jelica
AU  - Rajković, Jovana
AU  - Milanović, Slađan
AU  - Jaćević, Vesna
AU  - Miloradović, Zoran
AU  - Nežić, Lana
AU  - Novaković, Radmila
PY  - 2023
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1386
AB  - Cardiovascular diseases (CVDs) are a group of diseases with a very high rate of morbidity and mortality. The clinical presentation of CVDs can vary from asymptomatic to classic symptoms such as chest pain in patients with myocardial infarction. Current therapeutics for CVDs mainly target disease symptoms. The most common CVDs are coronary artery disease, acute myocardial infarction, atrial fibrillation, chronic heart failure, arterial hypertension, and valvular heart disease. In their treatment, conventional therapies and pharmacological therapies are used. However, the use of herbal medicines in the therapy of these diseases has also been reported in the literature, resulting in a need for critical evaluation of advances related to their use. Therefore, we carried out a narrative review of pharmacological and herbal therapeutic effects reported for these diseases. Data for this comprehensive review were obtained from electronic databases such as MedLine, PubMed, Web of Science, Scopus, and Google Scholar. Conventional therapy requires an individual approach to the patients, as when patients do not respond well, this often causes allergic effects or various other unwanted effects. Nowadays, medicinal plants as therapeutics are frequently used in different parts of the world. Preclinical/clinical pharmacology studies have confirmed that some bioactive compounds may have beneficial therapeutic effects in some common CVDs. The natural products analyzed in this review are promising phytochemicals for adjuvant and complementary drug candidates in CVDs pharmacotherapy, and some of them have already been approved by the FDA. There are insufficient clinical studies to compare the effectiveness of natural products compared to approved therapeutics for the treatment of CVDs. Further long-term studies are needed to accelerate the potential of using natural products for these diseases. Despite this undoubted beneficence on CVDs, there are no strong breakthroughs supporting the implementation of natural products in clinical practice. Nevertheless, they are promising agents in the supplementation and co-therapy of CVDs.
PB  - MDPI (Multidisciplinary Digital Publishing Institute)
T2  - Antioxidants
T2  - Antioxidants
T1  - Natural Substances vs. Approved Drugs in the Treatment of Main Cardiovascular Disorders—Is There a Breakthrough?
IS  - 12
SP  - 2088
VL  - 12
DO  - 10.3390/antiox12122088
ER  - 

@article{
author = "Grujić-Milanović, Jelica and Rajković, Jovana and Milanović, Slađan and Jaćević, Vesna and Miloradović, Zoran and Nežić, Lana and Novaković, Radmila",
year = "2023",
abstract = "Cardiovascular diseases (CVDs) are a group of diseases with a very high rate of morbidity and mortality. The clinical presentation of CVDs can vary from asymptomatic to classic symptoms such as chest pain in patients with myocardial infarction. Current therapeutics for CVDs mainly target disease symptoms. The most common CVDs are coronary artery disease, acute myocardial infarction, atrial fibrillation, chronic heart failure, arterial hypertension, and valvular heart disease. In their treatment, conventional therapies and pharmacological therapies are used. However, the use of herbal medicines in the therapy of these diseases has also been reported in the literature, resulting in a need for critical evaluation of advances related to their use. Therefore, we carried out a narrative review of pharmacological and herbal therapeutic effects reported for these diseases. Data for this comprehensive review were obtained from electronic databases such as MedLine, PubMed, Web of Science, Scopus, and Google Scholar. Conventional therapy requires an individual approach to the patients, as when patients do not respond well, this often causes allergic effects or various other unwanted effects. Nowadays, medicinal plants as therapeutics are frequently used in different parts of the world. Preclinical/clinical pharmacology studies have confirmed that some bioactive compounds may have beneficial therapeutic effects in some common CVDs. The natural products analyzed in this review are promising phytochemicals for adjuvant and complementary drug candidates in CVDs pharmacotherapy, and some of them have already been approved by the FDA. There are insufficient clinical studies to compare the effectiveness of natural products compared to approved therapeutics for the treatment of CVDs. Further long-term studies are needed to accelerate the potential of using natural products for these diseases. Despite this undoubted beneficence on CVDs, there are no strong breakthroughs supporting the implementation of natural products in clinical practice. Nevertheless, they are promising agents in the supplementation and co-therapy of CVDs.",
publisher = "MDPI (Multidisciplinary Digital Publishing Institute)",
journal = "Antioxidants, Antioxidants",
title = "Natural Substances vs. Approved Drugs in the Treatment of Main Cardiovascular Disorders—Is There a Breakthrough?",
number = "12",
pages = "2088",
volume = "12",
doi = "10.3390/antiox12122088"
}

Grujić-Milanović, J., Rajković, J., Milanović, S., Jaćević, V., Miloradović, Z., Nežić, L.,& Novaković, R.. (2023). Natural Substances vs. Approved Drugs in the Treatment of Main Cardiovascular Disorders—Is There a Breakthrough?. in Antioxidants
MDPI (Multidisciplinary Digital Publishing Institute)., 12(12), 2088.
https://doi.org/10.3390/antiox12122088

Grujić-Milanović J, Rajković J, Milanović S, Jaćević V, Miloradović Z, Nežić L, Novaković R. Natural Substances vs. Approved Drugs in the Treatment of Main Cardiovascular Disorders—Is There a Breakthrough?. in Antioxidants. 2023;12(12):2088.
doi:10.3390/antiox12122088 .

Grujić-Milanović, Jelica, Rajković, Jovana, Milanović, Slađan, Jaćević, Vesna, Miloradović, Zoran, Nežić, Lana, Novaković, Radmila, "Natural Substances vs. Approved Drugs in the Treatment of Main Cardiovascular Disorders—Is There a Breakthrough?" in Antioxidants, 12, no. 12 (2023):2088,
https://doi.org/10.3390/antiox12122088 . .

TY  - JOUR
AU  - Paunović, Danijela
AU  - Rajković, Jovana
AU  - Novaković, Radmila
AU  - Grujić-Milanović, Jelica
AU  - Mekky, Reham Hassan
AU  - Popa, Dragos
AU  - Calina, Daniela
AU  - Sharifi-Rad, Javad
PY  - 2023
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1387
AB  - Gossypol, a polyphenolic aldehyde derived from cottonseed plants, has seen a transformation in its pharmaceutical application from a male contraceptive to a candidate for cancer therapy. This shift is supported by its recognized antitumor properties, which have prompted its investigation in the treatment of various cancers and related inflammatory conditions. This review synthesizes the current understanding of gossypol as an anticancer agent, focusing on its pharmacological mechanisms, strategies to enhance its clinical efficacy, and the status of ongoing clinical evaluations.

The methodological approach to this review involved a systematic search across several scientific databases including the National Center for Biotechnology Information (NCBI), PubMed/MedLine, Google Scholar, Scopus, and TRIP. Studies were meticulously chosen to cover various aspects of gossypol, from its chemical structure and natural sources to its pharmacokinetics and confirmed anticancer efficacy. Specific MeSH terms and keywords related to gossypol’s antineoplastic applications guided the search strategy.

Results from selected pharmacological studies indicate that gossypol inhibits the Bcl-2 family of anti-apoptotic proteins, promoting apoptosis in tumor cells. Clinical trials, particularly phase I and II, reveal gossypol’s promise as an anticancer agent, demonstrating efficacy and manageable toxicity profiles. The review identifies the development of gossypol derivatives and novel carriers as avenues to enhance therapeutic outcomes and mitigate adverse effects.

Conclusively, gossypol represents a promising anticancer agent with considerable therapeutic potential. However, further research is needed to refine gossypol-based therapies, explore combination treatments, and verify their effectiveness across cancer types. The ongoing clinical trials continue to support its potential, suggesting a future where gossypol could play a significant role in cancer treatment protocols.
PB  - BioMed Central
T2  - Chinese Medicine
T1  - The potential roles of gossypol as anticancer agent: advances and future directions
IS  - 1
SP  - 163
VL  - 18
DO  - 10.1186/s13020-023-00869-8
ER  - 

@article{
author = "Paunović, Danijela and Rajković, Jovana and Novaković, Radmila and Grujić-Milanović, Jelica and Mekky, Reham Hassan and Popa, Dragos and Calina, Daniela and Sharifi-Rad, Javad",
year = "2023",
abstract = "Gossypol, a polyphenolic aldehyde derived from cottonseed plants, has seen a transformation in its pharmaceutical application from a male contraceptive to a candidate for cancer therapy. This shift is supported by its recognized antitumor properties, which have prompted its investigation in the treatment of various cancers and related inflammatory conditions. This review synthesizes the current understanding of gossypol as an anticancer agent, focusing on its pharmacological mechanisms, strategies to enhance its clinical efficacy, and the status of ongoing clinical evaluations.

The methodological approach to this review involved a systematic search across several scientific databases including the National Center for Biotechnology Information (NCBI), PubMed/MedLine, Google Scholar, Scopus, and TRIP. Studies were meticulously chosen to cover various aspects of gossypol, from its chemical structure and natural sources to its pharmacokinetics and confirmed anticancer efficacy. Specific MeSH terms and keywords related to gossypol’s antineoplastic applications guided the search strategy.

Results from selected pharmacological studies indicate that gossypol inhibits the Bcl-2 family of anti-apoptotic proteins, promoting apoptosis in tumor cells. Clinical trials, particularly phase I and II, reveal gossypol’s promise as an anticancer agent, demonstrating efficacy and manageable toxicity profiles. The review identifies the development of gossypol derivatives and novel carriers as avenues to enhance therapeutic outcomes and mitigate adverse effects.

Conclusively, gossypol represents a promising anticancer agent with considerable therapeutic potential. However, further research is needed to refine gossypol-based therapies, explore combination treatments, and verify their effectiveness across cancer types. The ongoing clinical trials continue to support its potential, suggesting a future where gossypol could play a significant role in cancer treatment protocols.",
publisher = "BioMed Central",
journal = "Chinese Medicine",
title = "The potential roles of gossypol as anticancer agent: advances and future directions",
number = "1",
pages = "163",
volume = "18",
doi = "10.1186/s13020-023-00869-8"
}

Paunović, D., Rajković, J., Novaković, R., Grujić-Milanović, J., Mekky, R. H., Popa, D., Calina, D.,& Sharifi-Rad, J.. (2023). The potential roles of gossypol as anticancer agent: advances and future directions. in Chinese Medicine
BioMed Central., 18(1), 163.
https://doi.org/10.1186/s13020-023-00869-8

Paunović D, Rajković J, Novaković R, Grujić-Milanović J, Mekky RH, Popa D, Calina D, Sharifi-Rad J. The potential roles of gossypol as anticancer agent: advances and future directions. in Chinese Medicine. 2023;18(1):163.
doi:10.1186/s13020-023-00869-8 .

Paunović, Danijela, Rajković, Jovana, Novaković, Radmila, Grujić-Milanović, Jelica, Mekky, Reham Hassan, Popa, Dragos, Calina, Daniela, Sharifi-Rad, Javad, "The potential roles of gossypol as anticancer agent: advances and future directions" in Chinese Medicine, 18, no. 1 (2023):163,
https://doi.org/10.1186/s13020-023-00869-8 . .

TY  - JOUR
AU  - Rajković, Jovana
AU  - Novaković, Radmila
AU  - Grujić-Milanović, Jelica
AU  - Ydyrys, Alibek
AU  - Ablaikhanova, Nurzhanat
AU  - Calina, Daniela
AU  - Sharifi-Rad, Javad
AU  - Al-Omari, Basem
PY  - 2023
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1302
AB  - Calotropin is a pharmacologically active compound isolated from milkweed plants like Calotropis procera, Calotropis gigantea, and Asclepias currasavica that belong to the Asclepiadaceae family. All of these plants are recognised as medical traditional plants used in Asian countries. Calotropin is identified as a highly potent cardenolide that has a similar chemical structure to cardiac glycosides (such as digoxin and digitoxin). During the last few years, cytotoxic and antitumor effects of cardenolides glycosides have been reported more frequently. Among cardenolides, calotropin is identified as the most promising agent. In this updated and comprehensive review, we aimed to analyze and discuss the specific mechanisms and molecular targets of calotropin in cancer treatment to open new perspectives for the adjuvant treatment of different types of cancer. The effects of calotropin on cancer have been extensively studied in preclinical pharmacological studies in vitro using cancer cell lines and in vivo in experimental animal models that have targeted antitumor mechanisms and anticancer signaling pathways. The analyzed information from the specialized literature was obtained from scientific databases until December 2022, mainly from PubMed/MedLine, Google Scholar, Scopus, Web of Science, and Science Direct databases using specific MeSH search terms. The results of our analysis demonstrate that calotropin can be a potential chemotherapeutic/chemopreventive adjunctive agent in cancer pharmacotherapeutic management.
PB  - Frontiers Media S.A.
T2  - Frontiers in Pharmacology
T1  - An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer
SP  - 1160616
VL  - 14
DO  - 10.3389/fphar.2023.1160616
ER  - 

@article{
author = "Rajković, Jovana and Novaković, Radmila and Grujić-Milanović, Jelica and Ydyrys, Alibek and Ablaikhanova, Nurzhanat and Calina, Daniela and Sharifi-Rad, Javad and Al-Omari, Basem",
year = "2023",
abstract = "Calotropin is a pharmacologically active compound isolated from milkweed plants like Calotropis procera, Calotropis gigantea, and Asclepias currasavica that belong to the Asclepiadaceae family. All of these plants are recognised as medical traditional plants used in Asian countries. Calotropin is identified as a highly potent cardenolide that has a similar chemical structure to cardiac glycosides (such as digoxin and digitoxin). During the last few years, cytotoxic and antitumor effects of cardenolides glycosides have been reported more frequently. Among cardenolides, calotropin is identified as the most promising agent. In this updated and comprehensive review, we aimed to analyze and discuss the specific mechanisms and molecular targets of calotropin in cancer treatment to open new perspectives for the adjuvant treatment of different types of cancer. The effects of calotropin on cancer have been extensively studied in preclinical pharmacological studies in vitro using cancer cell lines and in vivo in experimental animal models that have targeted antitumor mechanisms and anticancer signaling pathways. The analyzed information from the specialized literature was obtained from scientific databases until December 2022, mainly from PubMed/MedLine, Google Scholar, Scopus, Web of Science, and Science Direct databases using specific MeSH search terms. The results of our analysis demonstrate that calotropin can be a potential chemotherapeutic/chemopreventive adjunctive agent in cancer pharmacotherapeutic management.",
publisher = "Frontiers Media S.A.",
journal = "Frontiers in Pharmacology",
title = "An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer",
pages = "1160616",
volume = "14",
doi = "10.3389/fphar.2023.1160616"
}

Rajković, J., Novaković, R., Grujić-Milanović, J., Ydyrys, A., Ablaikhanova, N., Calina, D., Sharifi-Rad, J.,& Al-Omari, B.. (2023). An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer. in Frontiers in Pharmacology
Frontiers Media S.A.., 14, 1160616.
https://doi.org/10.3389/fphar.2023.1160616

Rajković J, Novaković R, Grujić-Milanović J, Ydyrys A, Ablaikhanova N, Calina D, Sharifi-Rad J, Al-Omari B. An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer. in Frontiers in Pharmacology. 2023;14:1160616.
doi:10.3389/fphar.2023.1160616 .

Rajković, Jovana, Novaković, Radmila, Grujić-Milanović, Jelica, Ydyrys, Alibek, Ablaikhanova, Nurzhanat, Calina, Daniela, Sharifi-Rad, Javad, Al-Omari, Basem, "An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer" in Frontiers in Pharmacology, 14 (2023):1160616,
https://doi.org/10.3389/fphar.2023.1160616 . .